COL6A4 Inhibitors
Chemical inhibitors of COL6A4 function primarily by modulating the extracellular matrix (ECM) and its remodeling process, which is crucial for the proper function of this protein. Matrix metalloproteinases (MMPs) are a group of enzymes that play a pivotal role in the breakdown of ECM components, and their activity is targeted by a variety of chemical inhibitors to control ECM dynamics that influence COL6A4 function. Batimastat and Marimastat are examples of such inhibitors that bind to MMPs and block their enzymatic activity. This action can lead to an altered ECM turnover and composition, affecting the functional integration of COL6A4 into the ECM. Similarly, Ilomastat and Prinomastat hinder MMPs' ability to degrade ECM proteins, thereby maintaining the structural integrity required for COL6A4's function. SB-3CT, with its selective inhibition of MMP2 and MMP9, reduces these enzymes' activity, resulting in a decrease in ECM component turnover that would otherwise impact the function of COL6A4.
The role of MMPs in ECM remodeling is further exemplified by the action of specific inhibitors like NSC 405020, which targets MMP14 allosterically, affecting its role in ECM protein processing. By inhibiting MMP14, NSC 405020 can indirectly influence the function of COL6A4 within the ECM. ARP 100 and PD 166793, as MMP2 inhibitors, and WAY-170523, as an MMP13 inhibitor, also contribute to the maintenance of the ECM structure, which is essential for COL6A4's role. Ro 28-2653, with its broad-spectrum MMP inhibition, prevents the degradation of collagenous matrices, thus affecting COL6A4's assembly and function. Lastly, RXP 470.1's selective inhibition of MMP14 further underscores the importance of MMP activity in regulating the ECM, which in turn influences the function of COL6A4. Through these various chemical interactions with MMPs, the integrity and remodeling of the ECM are controlled, which is central to the functional regulation of COL6A4.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Batimastat | 130370-60-4 | sc-203833 sc-203833A | 1 mg 10 mg | $175.00 $370.00 | 24 | |
Batimastat is a synthetic inhibitor of matrix metalloproteinases (MMPs), enzymes responsible for the degradation of extracellular matrix components. Inhibition of MMPs can lead to the functional inhibition of COL6A4 by preventing its proper assembly or remodeling within the extracellular matrix. | ||||||
Marimastat | 154039-60-8 | sc-202223 sc-202223A sc-202223B sc-202223C sc-202223E | 5 mg 10 mg 25 mg 50 mg 400 mg | $165.00 $214.00 $396.00 $617.00 $4804.00 | 19 | |
Marimastat is another MMP inhibitor, functioning similarly to Batimastat by blocking the activity of MMPs which could otherwise interact with COL6A4 during its integration into the extracellular matrix, thereby inhibiting the proper function of COL6A4. | ||||||
GM 6001 | 142880-36-2 | sc-203979 sc-203979A | 1 mg 5 mg | $75.00 $265.00 | 55 | |
Ilomastat, also known as GM6001, is an MMP inhibitor that can inhibit the degradation of the extracellular matrix, potentially preserving the structural integrity required for the function of COL6A4 and thus indirectly inhibiting COL6A4's functionality by stabilization. | ||||||
Prinomastat | 192329-42-3 | sc-507449 | 5 mg | $190.00 | ||
Prinomastat inhibits a range of MMPs, potentially leading to the functional inhibition of COL6A4 by hampering extracellular matrix remodeling, an essential process for the normal function of COL6A4. | ||||||
SB-3CT | 292605-14-2 | sc-205847 sc-205847A | 1 mg 5 mg | $100.00 $380.00 | 15 | |
SB-3CT selectively inhibits MMP2 and MMP9, which could result in the reduced turnover of the extracellular matrix components, thereby indirectly inhibiting the function of COL6A4 due to its reliance on a dynamic extracellular matrix for its function. | ||||||
NSC 405020 | 7497-07-6 | sc-477738 | 10 mg | $105.00 | ||
NSC 405020 is an allosteric inhibitor of MMP14, which is involved in the processing of extracellular matrix proteins. By inhibiting MMP14, this chemical may lead to the functional inhibition of COL6A4 by impeding extracellular matrix interactions necessary for COL6A4 function. | ||||||
ARP 100 | 704888-90-4 | sc-203522 | 5 mg | $121.00 | 26 | |
ARP 100 is a selective inhibitor of MMP2, which can lead to the functional inhibition of COL6A4 by disrupting the extracellular matrix remodeling that is crucial for the proper function of COL6A4. | ||||||
PD166793 | 199850-67-4 | sc-202709 | 5 mg | $147.00 | 6 | |
PD 166793 is an MMP inhibitor that can lead to the functional inhibition of COL6A4 by stabilizing the extracellular matrix structure, which is important for the mechanical properties that COL6A4 contributes to. | ||||||
WAY 170523 | 307002-73-9 | sc-361402 sc-361402A | 1 mg 10 mg | $275.00 $595.00 | 1 | |
WAY-170523 is a selective inhibitor of MMP13, an enzyme involved in the degradation of collagen and other extracellular matrix components. Inhibition of MMP13 can lead to the functional inhibition of COL6A4 by preserving extracellular matrix integrity. | ||||||